

What is claimed is:

1. A tetrahydro-5-oxo-2-furancarboxylic acid salt of amlodipine.
- 5        2. The tetrahydro-5-oxo-2-furancarboxylic acid salt of amlodipine as defined in claim 1, wherein the tetrahydro-5-oxo-2-furancarboxylic acid is (S)-tetrahydro-5-oxo-2-furancarboxylic acid or (R)-tetrahydro-5-oxo-2-furancarboxylic acid.
- 10       3. A method for preparing amlodipine tetrahydro-5-oxo-2-furancarboxylate, in which amlodipine is reacted with tetrahydro-5-oxo-2-furancarboxylic acid in an inert solvent.
- 15       4. The method as defined in claim 3, wherein the tetrahydro-5-oxo-2-furancarboxylic acid is (S)-tetrahydro-5-oxo-2-furancarboxylic acid or (1R)-(-)-10-tetrahydro-5-oxo-2-furancarboxylic acid.
- 20       5. A pharmaceutical composition for the treatment of ischemic cardiac disorders or hypertension, comprising a therapeutically effective amount of the tetrahydro-5-oxo-2-furancarboxylic acid salt of amlodipine of claim 1 or 2, and a pharmaceutically acceptable diluent or carrier.
6. The pharmaceutical composition as defined in claim 5, wherein the composition is in the dosage form of tablets or capsules.
- 25       7. The pharmaceutical composition as defined in claim 5, wherein the composition is in the dosage form of solutions or injectables.